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Abstract: Age-related macular degeneration (AMD) is responsible for the majority of visual 
impairment in the Western world. The role of cholesterol-lowering medications, HMG Co-A 
reductase inhibitors or statins, in reducing the risk of AMD or of delaying its progression has not 
been fully investigated. A 3-year prospective randomized controlled trial of 40 mg simvastatin 
per day compared to placebo in subjects at high risk of AMD progression is described. This 
paper outlines the primary aims of the Age-Related Maculopathy Statin Study (ARMSS), and the 
methodology involved. Standardized clinical grading of macular photographs and comparison 
of serial macular digital photographs, using the International grading scheme, form the basis for 
assessment of primary study outcomes. In addition, macular function is assessed at each visit 
with detailed psychophysical measurements of rod and cone function. Information collected in 
this study will assist in the assessment of the potential value of HMG Co-A reductase inhibitors 
(statins) in reducing the risk of AMD progression.
Keywords: age-related macular degeneration, progression, randomized controlled trial, HMG 
Co-A reductase inhibitor, statin, visual function
Introduction
Age related macular degeneration (AMD), a progressive late onset disease affect-
ing central vision, is the leading cause of irreversible blindness in western countries 
(Mitchell et al 1995; VanNewkirk et al 2000; Smith et al 2001). AMD prevalence 
increases exponentially with age, and with the increase in life expectancy, the bur-
den of this disease will increase over the coming decades (VanNewkirk et al 2000; 
Taylor 2002). Current treatment options for AMD are largely aimed at limiting the 
impact of the late neovascular complications of AMD. Currently only the AREDS 
supplementation has been shown to have some beneﬁ  t in reducing the risk of vision 
loss in some groups of high risk early AMD (Sackett and Schenning 2002). Further 
options are needed to slow the development of vision loss, and ultimately to prevent 
the disease from occurring.
HMG Co-A reductase inhibitors have pleotrophic actions, far wider than just 
their cholesterol-lowering properties for which they are mostly prescribed. Many of 
these actions may be beneﬁ  cial in reducing the risk of AMD. In addition to beneﬁ  ts 
achieved by reducing serum lipid levels (Hunninghake et al 1990; Bellosta et al 2000; 
Takemoto and Liao 2001; Watts 2001), the nonlipid-related effects of these drugs 
may be even more important in AMD pathogenesis (Guymer et al 1999; Pruefer et al 
1999; Spaide et al 1999; Bellosta et al 2000; Inoue et al 2000; Alvarez de Sotomayor 
and Andriantsitohaina 2001; Hageman et al 2001; Haimovici et al 2001; Hess and Clinical Interventions in Aging 2008:3(3) 582
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Fagan 2001; Jialal et al 2001; Kwak et al 2001; Takemoto 
and Liao 2001; Kuvin and Karas 2003; Friedman 2004). 
The recent genetic and pathological ﬁ  ndings implicating the 
complement pathway and inﬂ  ammation in the etiology of 
AMD (Edwards et al 2005; Hageman et al 2005; Haines et al 
2005; Klein et al 2005) suggest that the anti-inﬂ  ammatory 
actions of statins may also be valuable in AMD.
The association between AMD and the use of cholesterol-
lowering medications has been examined by a number of 
clinical studies, and there is a growing body of evidence that 
such an association exists, and it is inverse. The ﬁ  rst study to 
investigate a possible protective effect was a cross-sectional 
population-based study which found subjects who took 
statins had a one eleventh risk of having AMD compared to 
those who did not (Hall et al 2001). The Melbourne Visual 
Impairment Project (VIP) showed that, whilst there was 
a positive association with the actual prevalence of AMD 
and cholesterol-lowering medication (perhaps explained by 
a possible association between cardiovascular disease and 
AMD), participants on these medications were almost four 
times less likely to experience progression than those not 
taking medication (3.6% vs 13%), although this difference 
was not signiﬁ  cant (McCarty et al 2001a, 2001b).
In a large, nested case-control study, involving 550 cases 
and 5500 matched controls (McGwin et al 2003), cases of 
early AMD were 50% less likely to have ﬁ  lled a statin pre-
scription compared to those without early AMD, possibly 
supporting the protective effect of statins in the development 
of AMD.
A retrospective case series found that therapy with statins 
was associated with an almost 50% reduction in the risk of 
developing choroidal neovascularization (CNV) (Wilson 
et al 2004). An inverse association was also reported in a 
case-control study, based on the Atherosclerosis Risk in 
Communities cohort study, where use of cholesterol-lowering 
medications was inversely associated with AMD (McGwin 
et al 2005).
However, not all studies ﬁ  nd a protective effect, with 
a population-based case-control study, based on the UK 
General Practice Research Database, not ﬁ  nding a protective 
effect of statins (Smeeth et al 2005).The large population-
based Beaver Dam Eye Study, (BDES) and Rotterdam Eye 
Study (RES) found no protective effect of lipid-lowering 
medications on the 5-year incidence or progression of early 
AMD, despite the detected association of elevated HDL cho-
lesterol and AMD in RES (Klein et al 2003b; van Leeuwen 
et al 2004b). Though, only 3.9% of the BDES took statins 
at baseline (Klein et al 2003a). These analyses also included 
all lipid-lowering agents, not just statins. Similarly, Delcourt 
and colleagues (2001) reported an absence of association 
between lipid-lowering medications and late AMD in a cross 
sectional population-based study.
The limitation of such population-based studies is their 
reliance on subject recall with regard to medications taken. 
Statins have only relatively recently become a common 
medication amongst people over 50 years. As a result, 
many of these studies were underpowered in evaluating the 
effect of just statins, with a possibility of its effect being 
confounded by the inclusion of a diverse group of lipid-
lowering drugs. Also, perhaps the effect of statins requires 
a long follow up time to detect, especially when used in 
people already with signiﬁ  cant disease. Thus, 10-years of 
observation in the BMES showed statin to be protective 
for indistinct soft drusen, a key late AMD precursor lesion 
(Tan et al 2007). This ﬁ  nding did in fact reverse the previ-
ous negative ﬁ  ndings from the 5-year BMES follow up (van 
Leeuwen et al 2004b).
The role of statins in AMD is clearly topical and the 
current evidence is contradictory (see also Table 5). It has 
been addressed in a meta-analysis of eight studies where a 
relative risk of 0.74 was observed between users of lipid-
lowering medications in comparison to nonusers (95% CI 
0.55–1.00) (Chuo et al 2007). These pooled studies were very 
heterogeneous (Ri 0.85, p  0.001) and it was concluded 
that it was difﬁ  cult to determine the relationship between 
lipid-lowering medications and the risk of developing AMD 
with the existing literature, thereby highlighting the need for 
a prospective randomized controlled trial.
Although some have argued that a RCT would be difﬁ  cult 
to conduct due to the large sample size required, difﬁ  cul-
ties in having a placebo group and possible side effects of 
statins in subjects with normal cholesterol (Klein and Klein 
2004; Baker and Tarnopolsky 2005; Lamperti et al 2005), a 
growing body of evidence and conﬂ  icting results from the 
observational and case-control studies, along with a biologi-
cally plausible protective effect of statins, justiﬁ  es a need 
for a randomized controlled trial to deﬁ  nitively address the 
question of the potential use of statins in AMD. To date, no 
randomized controlled trial on statins in AMD has published 
any ﬁ  ndings.
Here we describe the design of a randomized controlled 
trial entitled Age-Related Maculopathy Statin Study 
(ARMSS), which aims to determine whether the use of HMG 
Co-A reductase inhibitor simvastatin is effective in prevent-
ing the progression of early AMD to the vision threatening 
complications of this disease.Clinical Interventions in Aging 2008:3(3) 583
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Materials and methods
Study design
ARMSS is a 3-year randomized, placebo-controlled, 
double-masked trial of simvastatin, 40 mg, versus placebo 
in a population of AMD-affected volunteers in Melbourne, 
Australia. The project has been approved by the Research 
and Ethics Committee of the Royal Victorian Eye and Ear 
Hospital, undertaken according to the Helsinki Declaration 
for the research on humans and registered with the Australian 
Clinical Trial Registry. Written informed consent was 
obtained from all participants prior to entry to the study.
Objectives
The primary objective of this study is to determine the effect 
of simvastatin (40 mg daily) in preventing or slowing the 
progression of age-related macular degeneration over a 3-year 
period, based on the grading of fundus photographs.
Secondary objectives of this study are:
a)  To assess the effect of simvastatin on macular visual 
function in early AMD.
b)  To explore the effect of genetic variability on the outcome 
in this cohort.
Recruitment
Participants were recruited from a previous study on AMD 
where participants were enrolled in the 1990’s with early 
AMD to identify risk factors for progression. After the end 
of that study participants were invited to enrol in the new 
study (Robman et al 2004). They were also enrolled from 
medical retinal clinics at the Royal Victorian Eye and Ear 
Hospital, Melbourne, Australia, and from private medical 
retinal specialists in Melbourne. Clinicians involved in 
the study approached patients with eligible ocular ﬁ  ndings 
and if interested the person was asked to attend the study 
clinics.
Eligibility criteria
Eligibility criteria (Table 1) were as follows: 1) age  
50 years; 2) absence of bilateral end stage AMD, glau-
coma, diabetes, significant cataract (cortical cataract 
 4/16 pupil diameter, posterior subcapsular cataract 
 1 mm2, nuclear cataract  Grade 2.0 based on the Wilmer 
system for lens opacity grading) (Taylor and West 1988), 
and any other ocular, neurological, or systemic disease 
that may compromise vision; 3) not using medications 
that may affect the retina (Ludvigh and McCarthy 1938; 
Said and Weale 1959; Gunkel and Gouras 1963); 4) lipid 
proﬁ  le not consistent with the National Heart Foundaton 
of Australia and the Cardiac Society of Australia and New 
Zealand guidelines for treatment with a lipid-lowering 
agent (see below and Table 1); 5) absence of conditions 
for which statins are clinically contraindicated; 6) no 
allergies or history of severe adverse reactions to statins; 
7) alanine aminotransferase (ALT) level not over 2 times 
the normal range.
AMD eligible criteria were: 1) high-risk feature of early 
AMD in both eyes; 2) 1 large soft druse(125 μm) or 
extensive intermediate drusen (63–124 μm) in both eyes; 3) 
one eye with late AMD and the other with pigment changes 
or soft drusen of any size. In the Macular Photocoagulation 
study (MPS) (MPSG 1991), a visual acuity of 20/60 or better 
in at least one eye was required.
To be included in this study, the fasting lipid proﬁ  le 
was not allowed to meet the National Heart Foundation of 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Male or female aged 50 years or older
VA better than or equal to 20/60 in one eye.
High risk drusen in both eyes: 1 large soft druse (125 
microns), or 10 intermediate drusen (63 microns and 
125 microns) OR
Late AMD (CNV, central GA) in one eye and any drusen or 
pigment change in the study eye
Bilateral end stage AMD (CNV, central GA)
Macula cannot be assessed in at least one eye
Medical and ophthalmic conditions which potentially affect visual function – 
including visually signiﬁ  cant cataract (deﬁ  ned by Wilmer grading method 
as nuclear opacity grade 2 or greater, cortical opacity greater than grade 2, 
posterior subcapsular cataract 1 mm2), history of diabetes and glaucoma
Cholesterol level within normal limits according to PBS 
criteria (Table 2)
Use of medications that may affect visual function, such 
as plaquenil, chloroquine, major tranquilizers.
Currently on cholesterol-lowering medication.
Use of statins is contraindicated 
Alanine aminotransferase (ALT) 2 times the upper limit of normal 
Previous severe adverse or allergic reactions to statins
Abbreviations: AMD, age-related macular degeneration; CNV, choroidal neovascularization; GA, geographic atrophy; PBS, pharmaceutical beneﬁ  ts schedule;   VA, visual acuity.Clinical Interventions in Aging 2008:3(3) 584
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Australia and the Cardiac Society of Australia and New 
Zealand guidelines for treatment with a lipid-lowering agent 
(Jones et al 1998; NHFA 2001) (Table 2). In a placebo-
controlled randomized trial, it was considered unethical 
to include individuals whose cholesterol levels required 
treatment. Thus, to be eligible, all recruits had to return 
“normal” cholesterol levels. If during the course of the 
trial a recruit needed to start treatment, their physician was 
asked to use simvastatin. The participant continued in an 
“off protocol” fashion in the study. Many potential recruits 
became ineligible, either because they were already taking 
statins or their pre-enrolment cholesterol test results were 
such that they were referred to their physician for consid-
eration of commencing cholesterol-lowering medication. 
A full listing of inclusion and exclusion criteria is outlined 
in Table 1.
Screening
Subjects who were referred to the study team were contacted 
by trained research staff and asked to provide a fasting lipid 
level, either from their general practitioner or through a 
request sent out to them from the study team. If lipid levels 
were elevated, the participants were not recruited but notiﬁ  ed 
and referred to their local doctors. Participants with lipid 
proﬁ  les that allowed entry into the study were invited along 
to the screening and baseline examination.
Having provided written informed consent, visual acuity 
and fundus examination was carried out via the baseline 
protocol outlined below to determine eligibility based on 
the ophthalmic assessment. Once this eligibility was con-
ﬁ  rmed, all remaining baseline examinations were performed 
(see Table 3).
Protocol
Baseline examination consisted of questionnaires, 
ophthalmic examination, blood draw, and visual function 
testing. The questionnaires (Table 3) gathered data on 
baseline demographics, general medical and family his-
tory, and risk factors for eye disease, including dietary 
intake, pharmaceutical intake, and speciﬁ  c medical con-
ditions. In addition, ethnic origin and family history of 
AMD, functional questionnaire (Impact of Visual Impair-
ment [IVI] Questionnaire) (Keeffe et al 1999; Hassell 
et al 2000), and cognitive function questionnaires were 
administered.
Ophthalmic examination included visual acuity, refrac-
tometry, ocular tonometry, fundus photography, and slit lamp 
examination. Best corrected visual acuity was measured at 
each time-point using a rear-illuminated Log MAR visual 
acuity chart at 4 metres and at 1 metre when required (Bailey 
and Lovie 1976). Failing this, recognition of hand movements 
or light perception was attempted.
Ophthalmic examination was performed with a standard 
slit lamp. All study participants were examined by a qualiﬁ  ed 
ophthalmologist, and, where clinically indicated, ﬂ  uorescein 
angiography was undertaken to exclude CNV.  A prior history 
of complications of late AMD was noted and conﬁ  rmed by 
examination.
Nonstereoscopic 45° macular images were taken with 
dilated pupils using a digital Canon CR6-45NM Non-
Mydriatic Retinal Camera (Saitama, Japan). Images were 
viewed immediately and repeated if unsatisfactory. Fundus 
grading of each image was conducted at a later stage by two 
trained graders using the “OptoMize PRO” software from 
Digital Healthcare Image Management System (Digital 
Healthcare Ltd [DH], Cambridge, UK) on a high resolution 
computer screen. Grading of macular characteristics was 
carried out according to the International Classiﬁ  cation and 
Grading System for AMD (Bird et al 1995). Each macula was 
graded for the absence or presence, size, location, number, 
centrality, and area covered by the following features: hard, 
intermediate, distinct and indistinct drusen, retinal pigment 
epithelium changes, geographic atrophy, and neovascular 
changes. Presence of other pathology was also recorded. 
Table 2 Pharmaceutical Beneﬁ  ts Schedule (PBS) qualifying criteria 
for subsidized statin prescriptions in Australia*
Patient conditions Lipid level for PBS 
subsidy
Existing coronary heart disease Cholesterol 4.0 mmol/L
Diabetes mellitus Cholesterol 6.5 mmol/L
Familial hypercholesterolemia or
Family history of coronary heart 




Cholesterol 5.5 mmol/L 
and HDL 1.0 mmol/L
HDL Cholesterol 1.0 mmol/L Cholesterol 6.5 mmol/L
Men 35–75 yrs of age
Postmenopausal women 
up to 75 yrs of age
Cholesterol 7.5 mmol/L 
or Triglycerides 4.0 mmol/L
If not eligible under the above  Cholesterol 9.0 mmol/L or
Triglycerides 8.0 mmol/L
Note: Adapted from the  November 2002 Schedule of Pharmaceutical Beneﬁ  ts. 
Abbreviations: HDL, high-density lipoprotein.Clinical Interventions in Aging 2008:3(3) 585
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Where disagreement occured between the two graders, the 
results were adjudicated by a retinal specialist (RG).
Periodical evaluation of grading was undertaken to assess 
intra- and inter-grader reproducibility. An unweighted kappa 
statistic with 95% conﬁ  dence interval was used as a measure 
of reliability.
Visual function testing
Visual function was monitored at each time-point of the study 
(every 6 months) in one eye only. Thus the study eye for these 
tests was the eye with visual acuity of 20/60 or greater. If both 
eyes meet all the other inclusion criteria as well as visual acuity, 
the eye with the more advanced stage of disease (according to 
the fundus appearance) was chosen as the study eye for visual 
function testing. All other assessments were carried out in both 
eyes. Patients with glaucoma, diabetes, signiﬁ  cant cataract and 
retinotoxic drugs were excluded because they could interfere 
with the interpretation of the functional tests.
Psychophysical measurements included colors percep-
tion thresholds (red and blue), spatiotemporal contrast 
sensitivity thresholds (4 and 14 Hz ﬂ  icker), central visual 
ﬁ  eld testing (thresholds for static and ﬂ  ickering targets up to 
10° eccentricity), dynamics of glare recovery (time constant 
and absolute threshold) and dark adaptation (time constant 
and absolute thresholds for both cone and rod components, 
as well as the rod-cone break).
Details of the testing procedure and technical 
characteristics have been described elsewhere (Phipps et al 
2003; Dimitrov et al 2008). Testing was conducted using 
specially developed software hosted in a G4 Macintosh 
(Apple, Cupertino, CA, USA) computer. Stimuli were 
presented on a calibrated and gamma-corrected (Metha 
et al 1993; Zele and Vingrys 2005) high-resolution CRT 
monitor (Hitachi Accuvue HM-4721-D; Hitachi; Tokyo; 
Japan) powered by an 8-bit NVIDIA video-card. The exam-
ination was controlled via a second monitor (examiner’s 
display). Color and ﬂ  icker thresholds and glare recovery 
were measured using a central (foveal) stimulus, 2° in size. 
The same target size was used for all cone tests to provide 
a direct functional comparison over a common retinal 
region. Dark adaptation dynamics were tested either with 
a foveal 4°stimulus or with 2° spots located at 4° and at 
10° in inferior ﬁ  eld. The 4° and 10° degree locations were 
chosen to compare vulnerable retinal regions (Curcio et al 
1996; Owsley et al 2000).
All visual function tests were conducted monocularly 
following pupil dilation. Prior to any testing, participants 
were adapted to ambient light levels (30 candela per m2) 
for at least 15 minutes. Subjects’ refractive correction for the 
test distance was worn over the study eye and the fellow eye 
was patched. A chin rest with forehead restraint was used 
to stabilize viewing distance. Psychophysical testing was 
Table 3 Schedule for procedures involved in the Age-related maculopathy statin study
Procedures Screening visit Baseline 
examination
Follow-up time in months




Blood draw for cholesterol and liver 
function tests
33 3 3 3 3 3
Blood draw for DNA tests 3
Medical history 33 3 3 3 3 3 3
Listing of medications 33 3 3 3 3 3 3
Mini-mental questionnaire 3
Impact of Visual Impairment (IVI) survey 3 3
Refraction 33 3 3 3 3 3
Visual acuity 33 3 3 3 3 3 3
Pupil dilation 33 3 3 3 3 3 3
Slit lamp examination 33 3 3 3 3 3 3
Macular photography 33 3 3 3 3 3
Visual function tests 33 3 3 3 3 3
Reporting of side effects 
Food Frequency Questionnaire 3
33 3 3 3 3 3Clinical Interventions in Aging 2008:3(3) 586
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preceded by a familiarisation and training period (2 min) 
at each visit.
Automated perimetry of the macular 10° ﬁ  eld was 
undertaken with static and ﬂ  ickering achromatic stimuli 
for the study eye of each participant using a Medmont 
M700 perimeter (Medmont Pty Ltd, Camberwell, Victoria, 
Australia) to identify focal areas of markedly decreased 
sensitivity so that these areas could be avoided in all 
subsequent testing. Flicker thresholds were measured at 
two temporal frequencies, 4 and 14Hz. Color thresholds 
were measured for isoluminant red and blue increments. 
Flickering and colored spots were presented for 1 second 
including a 200-ms ON and OFF cosine ramp. The subject’s 
task was to ﬁ  xate foveally the center of the display monitor 
indicated by two vertical and two horizontal rectangular 
markers (0.5° × 4° in size) and to respond to the presence 
of a stimulus, whose potential presence was signalled by 
an auditory tone. False positive and false negative trials 
were injected randomly into the test procedure at a 25% 
rate. Subjects were instructed to minimize the occurrence 
of false responses and any test that yielded 10% false 
responses was repeated.
Cone recovery was tracked after exposure of the study 
eye to an intense light (95% photopigment bleach). Prior 
to exposure, a criterion threshold was established with 
recovery time being measured for ﬁ  ve multiples of criterion 
threshold.
For cone and rod dark adaptation, the following param-
eters were measured: cone recovery rate (decades per min) 
and absolute threshold (log cd/m2), rod -cone transition time 
(rod-cone break; RCB; min) and rod-second-phase recovery 
rate (decades per min). These clinically important compo-
nents (Lamb 1981; Lamb and Pugh 2004; Dimitrov et al 
2008) were isolated by judicious selection of stimulus size, 
stimulus location, level of the pigment bleach, luminance 
output of the display monitor and test duration (30 min). The 
full test procedure, technical characteristics and modelling 
of the dynamics of the cone and rod recovery have been 
described elsewhere (Brown et al 1986; Owsley et al 2001; 
Phipps et al 2003; Dimitrov et al 2008).
In our preliminary studies, visual function tests showed 
high sensitivity and speciﬁ  city for AMD, eg, 93% of the 
AMD participants had at least one recovery parameter 
that was abnormal. The diagnostic capacity was high, eg, 
area under the curve in the receiver operator characteristic 
was 0.98 ± 0.01 for cone recovery and 0.92 ± 0.04 for rod 
recovery. The variability of the indices determined by our 
technique by retesting a subset of controls (n = 16) and 
patients (n = 24) after 16 ± 6.5 (mean ±SD) days show for 
rod-cone break a coefﬁ  cient of variation 32% (controls) and 
44% (AMD). This is similar to the variability found with 
clinical perimetry (Demirel and Vingrys 1994) indicating that 
our method has potential as a clinical application for the early 
detection of persons with AMD (Dimitrov et al 2008).
Blood tests
Fasting blood samples are taken at each visit to measure; 
fasting lipid profile, including total cholesterol level, 
high- and low-density lipoprotein cholesterol, triglyceride 
level, liver function test (to monitor for drug toxicity), and 
high sensitivity C-reactive protein, a measure of systemic 
inﬂ  ammation, is also taken at screening, 12 months, and 
3 years. Participants are notified and advice given to 
seek appropriate action if the results are abnormal. If the 
cholesterol levels rise once in the study, we request that the 
general practitioner uses simvastatin 40 mg if possible. If so, 
the participant stays in the study off protocol.
At baseline, blood samples were also taken for DNA 
analysis. DNA will be extracted and analysed for variants of 
AMD-related genes using the MassEXTEND reaction of the 
Sequenom platform. This will allow stratiﬁ  cation of AMD 
progression rates by genotypes, which has been important in 
our other progression cohort (Baird et al 2006, 2008).
Intervention
The intervention under assessment in this trial is simvas-
tatin as a single 40 mg/day dose. Both simvastatin and the 
placebo medication were supplied by Merck Sharp and 
Dohme (Sydney, Australia) in tablet form. The placebo 
tablets are indistinguishable by sight or taste from the active 
medication. The pharmacy department at the Royal Victorian 
Eye and Ear Hospital (RVEEH) packages the medication 
into numbered bottles allocated to two groups, A and B. 
A randomization schedule was prepared by a biostatistician 
using a permuted blocks allocation scheme. The participants 
received numbered bottles of either placebo or simvastatin 
tablets, randomized in a ratio of 1:1. The medication codes 
are stored in a secure location and are not accessible by study 
personnel involved in the examination of participants and 
the analysis of results.
Follow-up protocol
The study drug, at 40 mg daily, or placebo, was given over a 
3-year study period, with follow-up examination performed 
at 6-month intervals throughout the three years, according 
to the list of procedures in Table 3.Clinical Interventions in Aging 2008:3(3) 587
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Adverse events
Hepatotoxicity and rhabdomyolysis are serious side effects of 
statins (Alcocer 2003). Liver function tests were performed 
routinely to ensure no liver toxicity. If the participants com-
plained of unexplained muscle pain they were discontinued 
from the treatment. An independent safety committee reviews 
the adverse event rates in the placebo and active medication 
groups.
Study analysis
The primary objective of this randomized controlled trial is 
progression of AMD, either to the development of late stage 
AMD, deﬁ  ned as either CNV or central geographic atrophy 
or as progression through stages of early AMD. Secondary 
objectives are to measure changes in visual function results 
over time and to determine how the genotype inﬂ  uences 
progression.
Progression to late AMD
Appearance of the late complications of AMD, both central 
geographic atrophy (GA) and CNV, was adopted as the 
end point for an eye. Any symptoms or signs of CNV is 
immediately referred to a medical retina specialist (RG) 
and managed appropriately according to available standard 
treatments for CNV. If late AMD occurs in the one eye of 
two eligible eyes, the participants will continue to receive 
medication, and the course of the disease in the fellow 
eye will be observed. If both eyes reach late stage disease, 
the study treatment will be ceased and the subject will be 
exited from the study.
Progression of early AMD
Although the main study outcome is progression from 
early to late AMD, progression or reversal of early AMD 
features are also assessed. AMD status in each eye at 
baseline and at each follow-up visit is stratiﬁ  ed according 
to a 6-level severity scale as follows: Level 1 – no 
drusen/hard drusen only; Level 2 – intermediate drusen 
OR hyperpigmentation without hypopigmentation; Level 
3 – soft distinct or indistinct drusen OR hypopigmentation 
(with or without hyperpigmentation); Level 4 – soft distinct 
or indistinct drusen AND pigmentary abnormalities 
(hyper- or hypopigmentation); Level 5 – geographic 
atrophy; Level 6 – neovascular AMD (Taylor et al 2002; 
Tikellis et al 2007).
Progression is deﬁ  ned as either an increase by one or more 
levels in either eye from level 2, 3, or 4 at baseline to the 
follow up time point, or cases that showed an increase of 2 
or more steps in the speciﬁ  c grades of drusen or pigmentary 
changes as deﬁ  ned by the International classiﬁ  cation for 
AMD grading. For drusen, such grades involve a change in 
morphology, number, drusen type, location, size and area 
covered, whereas for pigmentary changes differences in 
size and location are assessed. We assumed a greater clini-
cal severity and a higher risk of developing late AMD with 
each successive level, based on previous ﬁ  ndings (Tikellis 
et al 2007). Regression of early AMD features may imply 
either a decrease in risk of progression to the late stage, or 
a replacement of these features by more severe signs of late 
AMD. All cases are to be veriﬁ  ed by an independent side-
by-side comparison of baseline and follow-up photos.
Progression based upon
visual function
The results of the visual function examinations will be ana-
lyzed for each test separately. Both ways will be employed 
to ensure the robustness of ﬁ  ndings:
(1) comparison of visual function in two treatment groups 
on a continuous scale, and
(2) event analysis, where we deﬁ  ne a case as progressed if a 
measurement in visual function test is outside of a 95% 
conﬁ  dence interval of the original distribution for this 
test on two consecutive biannual examinations.
These tests may provide additional information on disease 
severity and progression (Sunness et al 1989; AREDS 1999; 
Sackett and Schenning 2002). Rod and cone sensitivity may 
provide another method of assessing the effect of statins over 
a shorter time, long before a change in macular grading of 
AMD characteristics can be detected (Owsley et al 2000; 
Phipps et al 2003). Any test that could detect beneﬁ  t of an 
intervention more efﬁ  ciently than macula grading would 
offer great potential when studying other interventions in 
the future.
Genotype analysis
Haplotype analysis will be applied to genetic information 
collected in this study (Hageman et al 2005). A haplotype is 
a series of consecutive alleles on a particular chromosome. 
Haplotypes are broken down every generation However, 
recombination occurs preferentially in speciﬁ  c regions, 
known as haplotype blocks. Because alleles are correlated 
with each other in a haplotype block, knowing these struc-
tures in a population allows us to optimize the amount of the 
genetic information without having to genotype all potential 
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From our preliminary work we have established that 
we will need 4 tSNPs for the CFH gene, 2 tSNPs for the 
APOE gene, 22 tSNPs for the CFHR1-5 genes, 7 tSNPs 
for the B2/CF genes, and 25 tSNPs for the PLEKHA1/
LOC387715/HTRA1 gene cluster. Thus we will use a total 
of 60 SNPs across the regions of interest. Genotyping will be 
performed using the MassARRAY® platform (SEQUENOM) 
through the Australian Genome Research Facility (AGRF) 
in Brisbane, Australia. We have already undertaken use of 
this procedure in our preliminary study of the risk associated 
with the Y402H variant of the CFH gene.
Sample size
The sample size calculation was based on AMD change mea-
sured (1) traditionally, by visual/photographic detection, and 
(2) by detection of signiﬁ  cant changes in visual sensitivity 
and the time of rod-cone break in dark adaptation.
The photo-based detection rate of visible progression 
of high risk early AMD in the AREDS and CHARM 
Studies was about 5% per year (AREDS 2001; Tikellis 
et al 2007). In the Melbourne VIP, the number of people 
whose AMD progressed was 4 times lower in those on 
cholesterol-lowering medications than in those not on any 
such medication (McCarty et al 2001b). To detect a similar 
reduction in AMD progression, a sample size of 118 subjects 
in each arm, followed for three years, was needed to reach 
80% power at a 5% level of signiﬁ  cance.
We hypothesized, however, that we should detect changes 
in function earlier than clinical changes and thus have an 
answer regarding the use of statins at an earlier time than 
if we followed up participants purely on clinical criteria. 
Therefore, when calculating the sample size using functional 
outcomes, a smaller sample size would be required and yield 
greater experimental power.
For the power and sample size calculation based on visual 
function tests, we established repeatability of these tests and 
variability of visual function measurements in the sub-sets 
of the participants.
To determine repeatability of various measurements 
(thresholds for 4 and 14 Hz ﬂ  icker and red and blue colors, as 
well as rod-cone break in dark adaptation) the same examiner 
conducted repeated measurements on 26 participants with 2 
to 6 weeks interval.). Intra-class correlation coefﬁ  cients for 
these measurements were 0.74 for red, 0.84 for blue, and 
0.89 for both ﬂ  icker thresholds. It was 0.87 for the rod-cone 
break in dark adaptation.
Variability of these assays was measured in a sample of 
35 patients with early AMD. The coefﬁ  cient of variation 
(CV), which reﬂ  ected inter-participant performance, was 
used in our power analysis. Among the visual function 
tests, the highest inter-participant variability was found in 
blue sensitivity, with CV = 72% and the lowest CV = 58% 
in red sensitivity.
The variability of the data indicates that a sample size of 
50 patients per treatment group would be sufﬁ  cient to detect a 
22% to 41% change in sensitivity for the different functional 
methods over the trial period, with statistical power of 80% 
(Table 4). Likewise, our calculations show that with a sample 
of n = 50 (in each treatment group) we can detect a 3.4 min 
difference in rod-cone break.
Due to the length of time it took to recruit patients that 
fulﬁ  lled all the inclusion and exclusion criteria, and being 
cognizant of the expiry date of the special consignment of 
drug, we chose to cease recruitment when we achieved a 
sample size sufﬁ  cient for a difference to be detected in the 
functional aspects of the study, allowing for a 5%–10% 
attrition rate per year. Statistical power and sample size 
were calculated using the nQuery Advisor 7.0 software 
(Statistical Solutions, Cork, Ireland) and the StatMate 
software (Version 2.00, GraphPad Software, San Diego, 
California, USA).
Statistical analysis
Analysis will be performed using SPSS for Windows (SPSS 
Inc., Chicago, IL, USA). The difference in progression 
rates of AMD and incidence of late AMD will be compared 
between the two treatment groups. Comparisons of propor-
tions using Chi-square tests will be used for categorical data. 
Multivariate regression analysis will be used to control for 
confounders. Although randomization presumes achieving 
no major differences between two groups in the other than 
statin intake factors, we will control the analysis for age, as 
the age would have a signiﬁ  cant variation within each group, 
Table 4 The level of detectable change (%) in visual function 
for three sample sizes and two statistical powers, at a signiﬁ  cance 
level of 0.05 given our measured variability
Number of subjects per group
50 subjects 40 subjects 30 subjects
Statistical power 80% 90% 80% 90% 80% 90%
Red threshold 33 38 38 44 43 50
Blue threshold 41 47 47 53 53 61
Flicker threshold 38 44 44 53 49 57
Total static 37 43 43 49 49 56
DA – RCB 22 25 24 28 28 32
Abbreviation: DA – RCB, rod-conebreak in dark adaptation.Clinical Interventions in Aging 2008:3(3) 589
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Table 5 References on associations between cholesterol-lowering medications and development of AMD
Reference Details of study Conclusion
Delcourt et al 2001 Cross-sectional study
Age  60 years
N = 2584
Late AMD was not signiﬁ  cantly associated with current use of 
hypocholesterolemic drugs (OR 0.58, 95% CI 0.22–1.53), cardiovascular 
disease, known diabetes or blood pressure
Obesity (BMI 30) was associated with a two fold higher risk of late AMD 
(OR 2.29, 95% CI 1–5.23)
McCarty et al 2001a Cross-sectional study
Age  40 years
N = 4744
Past or present use of a cholesterol-lowering medication associated with 
an increased prevalence of early AMD (OR 1.72, 95% CI 1.18–2.49)
McCarty et al 2001b Population-based cohort study
Age  40 years
N = 4744
Participants on lipid-lowering medications were almost 4 times less 
likely to experience AMD progression (3.6% vs 13%). Findings were not 
signiﬁ  cant due to the small numbers of subjects in this group
Hall et al 2001 Cross-sectional study
Age 66–75 years
N = 379
AMD was more common amongst those who were not taking statins 
(p = 0.02). 22% of those not taking statins had AMD, whilst 4% on statins 
had AMD
Klein et al 2003a Population-based cohort study
Age 43–86 yrs
N = 3684 for 5 years of follow up
N = 2764 for 10 years of follow up
Higher serum HDL cholesterol at baseline was associated with pure 
geographic atrophy (RR = 1.29 per 10 mg/dl increase (1.05–1.58).
Only 3.9% of the studied population were taking statins at baseline
No signiﬁ  cant association between the use of lipid-lowering medication 
(including nicotinic acid, ﬁ  bric acid derivatives, bile acid sequestrants and 
statins) with early AMD incidence or progression
van Leeuwen et al 2003 Population-based cohort study
Age  55 years
N = 4822
452 on lipid-lowering medications
Follow up at 2 and 6.5 years (26,781 
person years)
No signiﬁ  cant association between the use of lipid-lowering medication 
(including nicotinic acid, ﬁ  bric acid derivatives, bile acid sequestrants and 
statins) with early AMD incidence or progression (HR 1.0, 95% CI 0.7–1.5)
McGwin et al 2003 Nested case-control study
Age  50 years
550 cases of AMD and 5500 matched 
controls
Cases of early AMD were 70% less likely to have ﬁ  lled a statin prescription 
in comparison to those without early AMD (OR 0.30, 95% CI 0.21–0.45)
Number of ﬁ  lled prescriptions was taken as an indication of statin use, 
rather than subject reported use
Wilson et al 2004 Retrospective consecutive case series
Age  60 years, all subjects had AMD
Statins use was associated with an almost 50% reduction in the risk of 
developing CNV (HR 0.54, 95% CI 0.33–0.87)
Triglyceride levels were positively correlated with the rate of CNV 
(HR 1.30, 95% CI 1.02–1.66)
McGwin et al 2005 Case-control study based on the 
population-based cohort
Age 45–65yrs
Use of cholesterol-lowering medications was inversely associated with AMD
11% of those with AMD were using these medications, compared to 12.3% 
of controls (OR 0.89, 95% CI 0.63–0.99)
871 AMD cases, 11,717 controls
Smeeth et al 2005 Population-based case-control study
Age  50 years
18,007 AMD cases and 86,169 age 
and gender matched controls
No signiﬁ  cant association between the use of statins and a diagnosis of 
AMD (OR 0.93, 95% CI 0.81–1.07)
McGwin et al 2006 Case-control study
Age  65 years
390 AMD cases , 2365 controls
Cases of AMD were more likely to be older and white than controls 
(p  0.001)
Nearly equal proportions of cases and controls used cholesterol-lowering 
medications (OR 1.06, 95% CI 0.81–1.40)
Tan et al 2007 Population-based cohort study
Age  50 years
N = 3654 at baseline
N = 1952 at 10 years
Those on statins had a reduced risk of developing indistinct soft drusen 
at 10 years (HR 0.33; 95% CI 0.13–0.84) and also had a borderline 
nonsigniﬁ  cant reduced risk of any AMD
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and also for gender, smoking status and other variables, 
which would retain in the ﬁ  nal model if they change the β 
coefﬁ  cients by more than 5%.
The analysis will be conducted on an ‘intention to treat’ 
basis, incorporating the total study population. An ‘on 
protocol’ analysis will also be performed. Special attention 
will be given to the handling of patients who did not return for 
examination and photography. Adverse events and reasons 
for withdrawals will be analyzed. For the withdrawals the 
latest data obtained prior to the withdrawal will be carried 
forward to the following years, to ensure that the outcome 
from these participants would not be missed in the analysis. 
Kaplan-Meier survival analysis with log rank test statistics for 
equality of survival distributions between the two treatment 
groups will be applied to the data on reaching the end-point 
of late AMD.
Psychophysical outcomes will be analyzed using para-
metric and nonparametric comparisons between the two 
treatment groups. A receiver operator characteristic will be 
determined for each test in order to consider test sensitivity 
and speciﬁ  city at different criteria, positive and negative 
predictive values and diagnostic accuracy (Hanley et al 1983; 
Ariyasu et al 1996). The capacity of each test to discriminate 
between diseased and control groups will be determined by 
calculating the either d-prime or a-prime values. The a-prime 
is a nonparametric index of discriminability.
In the genetic arm of the study, the haplotype risks will 
be established using logistic regression, with case status of 
AMD as the binary outcome. The likelihood ratio test will be 
used to compare dominant, recessive and additive models for 
the effect of SNP haplotypes with the unconstrained model 
(allowing separate effects in each haplotype category).
A combined effect of genetic and environmental risks will 
be explored in multivariate regression analysis, and possible 
interaction between various risk factors will be investigated   
using quantitative measures of interaction (Rothman and 
Greenland 1998).
Recruitment results
Recruitment started in April 2003 and continued until the 
end of 2006. A total of 271 people were referred, based upon 
the ocular pathology. Of these, 152 fulﬁ  lled the eligibility 
criteria for recruitment. Participants were excluded for 
the following reasons: development of bilateral late AMD 
(n = 20), high cholesterol levels requiring cholesterol-
lowering medications (n = 7), already on cholesterol-lowering 
medications (n = 18), had low vision (n = 5), glaucoma 
(n = 16), signiﬁ  cant cataract (n = 12), or diabetes, major 
illness or cancer (n = 22), had difﬁ  culty understanding the 
study requirements (n = 6), were unable to attend the study 
centre (n = 8); and 5 people deceased prior to recruitment 
into ARMSS. A further 38 apparently eligible participants 
chose not to enroll in the study 114 participants were ﬁ  nally 
enrolled and randomized (Figure 1). The recruitment was 
difﬁ  cult due to the stringent eligibility criteria to allow 
meaningful results from the functional tests and to exclude 
participants who need treatment with statins.
The average age of the enrolled participants was 74.6 ± 
7.0 years, with 77 (67.5%) being female, 6 (5.3%) current 
and 58 (50.9%) former smokers. Of the total sample, 
64 participants had early AMD in both eyes and 50 participants 
had one eye with early AMD and the other eye had either 
geographic atrophy or neovascular AMD. To date, mid-2008, 
for 78% of the enrolled participants a three-year treatment 
period is completed. The study continues, with 23% of the 
enrolled participants still to be followed up. We anticipate the 
examinations to be ﬁ  nished by the end of 2009 and results are 
expected in 2010.
Table 5 (Continued )
Reference Details of study Conclusion
Klein et al 2007a Randomized clinical trial of hormone 
replacement therapies
Age 50–79 years
N = 4288 women
Use of statins was inversely associated with soft drusen (OR 0.81, 95% 
CI 0.68–0.96), but not with early or advanced AMD
Klein et al 2007b Population-based cohort study
Age 43–86 years
N = 2962 at baseline
N = 2204 at 5 years
Statin use was not associated with the ﬁ  ve year incidence of:
Early AMD (OR 1.16 95% CI 0.71–1.91)
Late AMD (OR 1.27 95% CI 0.60-2.69)
Progression of AMD (OR 1.16 95% CI 0.75–1.78)
Friedman et al 2005
IOVS 46 (Suppl):199
Case-control study
94 cases of AMD, 54 controls
Those on statins had a reduced risk of AMD (RR 0.50, 95% CI: 0.23–1.09)
Abbreviations: AMD, age-related macular degeneration; BMI, body mass index; CI, conﬁ  dence interval; HR, hazard ratio; OR, odds ratio; RR, relative risk.Clinical Interventions in Aging 2008:3(3) 591
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Conclusion
AMD is a debilitating and costly disease for both the indi-
vidual and the community. We have very little to offer people 
who are at risk of this disease in terms of prevention and slow-
ing progression. Statins are lipid-lowering, anti-inﬂ  ammatory 
agents with pleiotropic actions. Emerging knowledge about 
AMD genetics and pathology suggests a possible role for 
statins in prevention and delaying progression of AMD.
However, whilst there is increasing epidemiological 
evidence to support the notion of using lipid-lowering 
medications in AMD, not all evidence supports this hypothesis. 
To date there is no published randomized clinical trial designed 
to answer this question. This paper outlines how such a 
trial is being run. The ARMSS trial has ﬁ  nished recruiting. 
Implemented measures of visual function will add invaluable 
additional information to that obtained from tradition fundus 
photographs and grading. If a protective effect is found for the 
long-term use of statin as a prophylactic, preventative therapy 
for AMD development, or progression, then this would be a 
feasible strategy to adopt.
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